There was initial concern that the concomitant treatment of COVID-19 patients with ACEIs or ARBs would enhance ACE2 expression and hence susceptibility to infection and pathophysiological sequelae, but fortunately, this has not been supported by clinical evidence (28). This evidence concerns the gene ACE2 and infection.